Pancreatic cancer produces debilitating pain that opioids often ineffectively manage. The suboptimal efficacy of celiac plexus neurolysis (CPN) might result from brief contact of the injectate with celiac ganglia. We compared the effects of endoscopic ultrasound-guided celiac ganglia neurolysis (CGN) vs the effects of CPN on pain, quality of life (QOL), and survival.
P ain develops in 90% of patients with pancreatic ductal adenocarcinoma (PDAC) over their disease course. 1 As few patients have resectable disease, the focus of therapy is often to optimize pain management and quality of life (QOL). The World Health Organization recommends stepwise care with initial nonsteroidal use, followed by opioids for refractory pain. 2 However; opioids frequently provide inadequate pain relief and are associated with adverse effects (AEs). Celiac neurolysis (CN), in which a neurolytic agent and anesthetic are injected into the celiac plexus, is performed to augment pain relief and is recommended by the National Comprehensive Cancer Network. 3 While CN has historically been performed via a percutaneous approach, endoscopic ultrasound (EUS)-guided CN has become the favored approach in some centers. Regardless of the means of guidance, the conventional technique is celiac plexus neurolysis (CPN) that involves diffuse injection throughout the celiac plexus region ( Figure 1 , left and Figure 1 , right).
The celiac plexus transmits pain sensation via preganglionic sympathetic fibers that arise from the pancreas and connect within the ganglia. 4 Efferent fibers form the splanchnic nerves that synapse at the dorsal root ganglia and enter the spinal cord. 4 Injected alcohol induces neurolysis by solubilizing lipid compounds and precipitating cell membrane proteins, leading to nerve fiber demyelination and axonal degeneration. 5 Meta-analyses and evidence-based reviews generally conclude that CPN provides modest pain relief with minimal impact on morphine response and QOL, [6] [7] [8] [9] [10] [11] with uncertain impact on survival. 8, [12] [13] [14] [15] [16] In a retrospective study, we found that celiac ganglia neurolysis (CGN) was associated with shorter survival than CPN. 15 This study was designed to address limitations associated with our prior retrospective study. The suboptimal efficacy of CPN may be partially explained by the rapid spread of the injectate and brief contact with celiac ganglia (CG) that contain the majority of neural tissues and synapses, thereby limiting the degree of neurolysis. 17 The discovery that CG can be visualized and targeted by EUS, allows an alternative technique termed CGN in which a neurolytic solution is injected directly into CG ( Figure 1 , right and Figure 2 , right). [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The primary aims of our prospective, randomized, double-blind controlled trial was to test the hypothesis that CGN with injection of the residual volume using conventional CPN techniques improves pain control and QOL and prolongs survival when compared with CPN alone. We secondarily compared the techniques in terms of morphine response, performance status, secondary neurolytic effects, and AEs. Artwork and endoscopic ultrasound demonstrating broad spread of the injectate (in blue) following celiac plexus neurolysis that may limit the degree of neurolysis (left panels) and efficacy vs direct intraganglionic injection with celiac ganglia neurolysis (right panels).
What You Need to Know
Background Most meta-analyses and systemic reviews reported that celiac plexus neurolysis reduces pain in approximately 50%-80% of patients for 4-8 weeks, with a significant although limited advantage over analgesic therapy. While some data indicated that celiac plexus neurolysis (CPN) improves survival, most reported no benefit. Celiac ganglia neurolysis (CGN) has been theorized to improve pain control, quality of life, and survival when compared with conventional celiac plexus neurolysis.
Findings CGN results in a significantly shortened survival of 5.6 months vs 10.5 months as compared with conventional celiac plexus neurolysis. CGN and CPN provide similar pain relief and quality of life.
Implications for patient care
The role of CGN must be carefully reconsidered, given the data demonstrating that CGN shortens life expectancy of patients with pancreatic cancer without providing other clinical benefits over CPN. For clinicians contemplating performing CGN, we advise careful and thorough patient written informed consent that conveys the potential negative impact and unproven benefit of CGN when compared with CPN.
Methods

Study Design and Patients
We performed a prospective, randomized, double-blind control trial. We had access to the study data and reviewed and approved the final manuscript. The study was approved by the Institutional Review Board (# 09-005037) and all patients provided written informed consent. Patients were recruited from the Multidisciplinary Pancreas Clinic. Eligibility required 1) biopsy confirmation of PDAC; 2) abdominal pain (average intensity in prior 24 hours !3 on a numerical rating scale [NRS], !1 hour/day, relatively stable for !7 days) or opioid-requiring; and 3) unresectable disease as determined by the pancreatobiliary surgeon or patient refusing resection. Exclusion criteria included 1) coagulopathy (international normalized ratio >1.5 or platelets <50,000 Â 10 9 /L); 2) prior pancreatic resection, chemotherapy, radiotherapy, or CN; or 3) tumor infiltration of the celiac plexus.
Randomization and Masking
The Division of Biostatistics conducted computer randomization in blocks of 4, based on the technique (CPN vs CGN) and tumor stage (stage I-III vs IV).
Randomization disclosure occurred following confirmation of PDAC by telecytology, if not previously obtained. Following stratification, an administrative assistant, not involved in the study, opened in sequence a sealed envelope containing the assignment. The procedure note indicated that CN had been performed without stating the technique. The study team consisted of members with unique roles to maintain study blinding. Physicians responsible for pain management, chemoradiotherapy, and surgery were blinded to the randomized intervention. The blinded observer was a research nurse who performed all patient assessments. The operator (endosonographer) by necessity was not blinded to the intervention, but was not otherwise involved in the patient care. Clinical care was not guided by study participation.
Procedures
Uniform EUS Interventions. EUS (GF-UC140P-AL5, or GF-UCT180; Olympus Medical Systems, Center Valley, PA) was performed with fine needle aspiration with telecytology confirmation when a prior diagnosis was not available. For the CN, a separate 22-gauge needle was used to inject bupivacaine (0.25%, 4 mL) and alcohol (99%, 20 mL). Saline (1 L) was administered to minimize the risk of postural hypotension. Deep sedation or general anesthesia was used and antibiotics were not administered.
Celiac Plexus Neurolysis. Standard bilateral injection was performed by placing the needle tip 5-10 mm along both sides of the aorta at the level of the celiac trunk origin, administering half of the injectate to both sites.
Celiac Ganglia Neurolysis. The celiac ganglia were numbered and measured as previously reported. 18, 19 The needle was advanced to the deepest aspect of 5 ganglia, injecting 3 mL/ganglion, upon slow withdrawal. The term CGN was used to simplify the discussion; however, patients randomized to CGN underwent initial CGN, with injection of the residual volume using conventional CPN techniques. We completed a study (publication in press) involving 504 patients and reported 94.7% accuracy for distinguishing celiac ganglia from lymph nodes, signifying correct targeting in the majority of patients.
Outcomes and Assessments
Primary outcomes included pain control (12 week), QOL (12 week), and survival (overall median and 12 months). Secondary aims included morphine response, performance status, secondary neurolytic effects, and AEs. Data were obtained by the research nurse via in-person discussions, written questionnaires, and telephone conversations with the patient, spouse, or designated caregiver.
Baseline (Day -3 to 0). 1) Pain character and intensity: NRS (0 ¼ no pain, 10 ¼ worst pain imaginable); 2) QOL: Uniscale Patient Satisfaction Scale, 21 Functional Assessment of Cancer Therapy (FACT-Hep), 14 Memorial Symptom Assessment Scale, 22 Survivorship methods such as the Kaplan-Meier method and Cox proportional hazards regression were used to assess the time-to-event outcomes of death and first pain AE morphine response (with a competing risk of death). Morphine response was defined by looking at the CPN group to determine the average change in morphine dose during a 4-week period, and calculated a 95% CI for this. The lower confidence limit from the interval created was used as the threshold below which was deemed to be a morphine response. Multivariable models for these outcomes were created using a prespecified set of covariates. The associations between secondary effects and outcomes of interest were evaluated using logistic regression both for the overall cohort and by each group (CPN and CGN) separately.
All statistical tests were 2 sided and P < .05 was statistically significant. The analysis was performed using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Between March 2010 and March 2014, we prospectively enrolled 110 patients including 53 (age 66.4 AE 11.6 years; 66% men) randomized to CPN and 57 (age 66.8 AE 10.0 years; 56% men) to CGN. Another 94 patients were excluded for not meeting eligibility requirements (n ¼ 67) or refusal to participate (n ¼ 27). Seven patients assigned to CGN received CPN due to absence of visible ganglia, per protocol resulting in 60 and 50 patients treated by CPN vs CGN, respectively (Appendix 1). To determine the impact of reassignment, an extensive panel of baseline characteristics was analyzed: 1) as treated and 2) as randomized ( Table 1) . There were no prognostic differences between these groups at baseline, indicating a lack of bias secondary to reassignment. Ascites was present in 9 patients (CPN, n ¼ 5; CGN, n ¼ 4). The diagnosis of PDAC was established during the index exam in 101 of 110 patients and for remaining 9 patients was established 6 (interquartile range, 4-14) days prior. Per protocol, patients randomized to CGN underwent initial CGN (7.2 AE 3.5 mL), with injection of the residual volume using conventional CPN techniques (14.7 AE 4.5 mL).
Due to the intense nature of the prolonged follow-up, 12 patients (6 in each treatment group) enrolled and permitted monitoring only to assess survival and 10 day follow-up to assess secondary neurolytic effects, and AEs. Data from 110 patients (CPN, n ¼ 60; CGN, n ¼ 50) was included when assessing survival, secondary neurolytic effects, and AEs; whereas data from 98 patients (CPN, n ¼ 54; CGN, n ¼ 44) was used to assess pain response, QOL, morphine response, and performance status.
Endpoints
Pain Response. Based on the strict definition of pain response, CGN provided slightly better pain response compared with CPN at each time interval (Table 2 and Appendix 2). The response rates at 12 weeks were 40.4% vs 46.2% for CPN vs CGN, respectively (P ¼ .84). Using less stringent criteria of improved NRS by !2 or !1 points, at 12 weeks CGN and CPN provided pain relief in 50.0% vs 47.6%, and 65.4% vs 64.3%, respectively (Appendix 3 and 4). While by univariate analysis several factors were associated with a pain response, based on multivariable analysis no feature correlated with pain response, including the CN technique (Appendix 5 and 6).
QOL and Performance Status. The QOL measures (FACT-Hep score, Memorial Symptom Assessment Scale score, and Brief Pain Inventory pain interference score) each improved over 12 weeks within both treatment groups and for the entire cohort, with the latter 2 For all patients, regardless of therapy, the volume of ganglia was calculated based on the typical ellipsoid shape of ganglia using the formula: Volume ¼ (4/3) Â pi Â radius1 Â radius2 Â radius3). The collective volume of all ganglia was added for each patient to obtain the total volume. Table 4) . Specifically in those with nonmetastatic disease, survival was worse for CGN compared with CPN (HR, 2.95; 95% CI, 1.61-5.45; P < .001). There was no difference between groups for those with metastatic disease (HR, 0.89; 95% CI, 0.52-1.51; P ¼ .67) (Figure 2) .
Morphine Response. The morphine equivalent dose gradually increased from baseline to week 12, after which the dose plateaued or nonsignificantly decreased within the CPN and CGN cohorts, respectively (Appendix 9). The morphine dose at 12 weeks was 93 mg/day vs 105 mg/day (P ¼ . Secondary Neurolytic Effects, Adverse Events. CGN was more likely to induce a secondary neurolytic effect (55.1% vs 23.3%; P < .001), in particular with transient pain exacerbation (44.9% vs 8.3%; P < .001), than CPN was (Appendix 12). We anticipated that the development of secondary effects conveyed a greater likelihood of pain relief, which was not borne out by the data (Appendix 13). However, the development of any secondary effect was associated with a morphine response (odds ratio, 4.19; 95% CI, 1.74-10.08) as was the specific occurrence of a transient pain exacerbation (odds ratio, 5.9; 95% CI, 1.98-17.54). One patient who underwent CGN developed irreversible paralysis secondary to spinal cord infarction. 26 No other procedure-related AEs were reported.
Discussion
Our prospective, randomized, double-blind trial demonstrated that when compared with CPN alone, combined CGN and CPN increases the harmful effects manifest by a significantly shortened survival and greater risk of secondary neurolytic effects, without improving other clinical endpoints such as QOL, pain DTotal MSAS score (weekbaseline) control, and opioid intake. In addition, while the CPN cohort with stage IV disease demonstrated a morphine response, the CGN cohort did not, thereby suggesting another limitation of CGN. Our results are in contrast to the purported heightened efficacy provided by CGN that has led many to abandon CPN in favor of CGN. 27 Our data are strongly likely to raise controversy as to the utility and role of performing CGN. Similarly, the role of CGN was also questioned in a clinical and human cadaver study and found that the distribution of injectate spread far beyond the injected ganglia. 28 PDAC is associated with debilitating pain that is attributed to tumor-associated morphologic, immune, inflammatory, and growth factor alterations within pancreatic and peripancreatic nerves. 1, 19 Pain negatively impacts QOL and performance status, thereby hindering ones candidacy for surgery and chemotherapy. 1 Pain and stress are also linked to shorter survival. 1 Opioids ineffectively manage the pain and produce side effects that further decline clinical status, and may promote tumor growth and recurrence. 29 Most meta-analyses find that CN reduces pain in 50%-80% of patients for 4-8 weeks, with a significant although limited advantage over analgesic therapy.
6-11 A double-blinded, randomized, sham-controlled trial evaluated 100 patients comparing percutaneous CPN to analgesic therapy with sham injection.
14 At 1 week, both cohorts experienced improved pain (P .01) and QOL (P < .001) with an advantage for percutaneous CPN (P ¼ .005). Opioid consumption, QOL, and survival duration were similar between groups. In our study, using the strictest definition of a pain response (decrease NRS !3 points or !50%) CGN provided a nonsignificant benefit with 46.2% experiencing pain relief vs 40.4% for CPN at 12 weeks.
Most report stable or increased opioid use following CN, leaving many to suggest that the practical goal is to slow the rate of escalation rather than to decrease or eliminate use. 10, 11, 14, 19 In our study, opioid consumption increased until week 12, and thereafter plateaued or nonsignificantly decreased within the CPN and CGN cohorts, respectively. While secondary effects did not predict a pain response, their occurrence did correlate with morphine response, particularly within the CGN cohort, suggesting the greater biologic effect of this more targeted therapy.
While some published data indicate that CN improves survival, 12 ,13 most report no benefit. 8, 14, 16, 30 In a prior retrospective study, we evaluated whether CN, irrespective of technique, prolongs survival. 15 We matched 417 patients who underwent CN to 840 controls and found that CGN was associated with shorter survival than CPN. Methodological limitations left uncertainty whether the survival difference resulted from procedural vs clinical and tumor-associated features. Our current study was carefully designed to consider these important variables and confirmed on multivariate analysis that CGN is independently associated with a shorter survival.
There are inconclusive data regarding the effect of CN on QOL, with most reporting no improvement. 14, 21, 30, 31 A meta-analysis failed to reach a conclusion given the varied QOL scales employed, 11 which led to our use of several QOL scales. While the QOL measures improved over 12 weeks among our entire cohort, both techniques were associated with similar improvements. It is unclear why the QOL measures improved while the performance status deteriorated given the overlap in some criteria.
A study limitation is the absence of a placebo control group. Also addition, we can neither mechanistically account for the shorter survival occurring with CGN nor identify unknown confounders or sources of bias. Preclinical data demonstrate that neural ablation or denervation directly and indirectly decrease tumorigenesis, slow tumor progression, and prevent cancer development. 32, 33 It is possible that targeted injection of a caustic agent within CG induces local or systemic immune, inflammatory, or metabolic pathways that enhanced tumor growth and spread, thereby promoting tumor-associated death. It is also possible that CGN negatively impacts other organs and therefore secondarily impacts survival. Future studies should consider these potential mechanisms in their design.
In conclusion, while we hypothesized that combined CGN and CPN enhances neurolysis and clinical benefit, our data indicate that it may conversely enhance the deleterious effects with significantly shortened survival without improving other clinical endpoints when compared with conventional CPN. The development of paralysis following CG must be considered, although paralysis has rarely been reported following percutaneous and EUS-guided CPN. We question the role of CGN 34 and recognize that the multimodal mechanisms of PDAC-induced pain may not be adequately managed by any CN technique and believe that a well-designed study is needed to compare CPN to a placebo control group given the suboptimal performance of CPN in the current and prior studies.
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